Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
News
Inside Waisman: Meet Lindsay McCary
As a third year graduate student in school psychology at the University of South Carolina, Lindsay McCary, PhD, was looking for a new advisor to help her with her dissertation. At the time, Jane Roberts, PhD, had just joined the Department of Psychology and had some data available on younger children with the genetic disorder fragile X syndrome (FXS). McCary was immediately fascinated by the new professor’s research because it integrated both behavioral and physiological data to examine an individual’s observable characteristics.
Friends present staff, students and family awards
The Friends of the Waisman hosts this annual event for members of the Friends organization; community supporters of the Waisman Center; and Waisman Center faculty, staff, and students. The 2020 Awards were presented at a virtual meeting on August 18 2020.
Running toward renewal: new study links physical activity with cognitive health
Research has shown voluntary running is an activity most commonly associated with the reversal of negative impacts of aging and neurodegeneration, but little is understood about why that is.
UW researchers devise approach to treat rare, incurable form of blindness
Waisman Center investigator David Gamm, MD, PhD, and Waisman affiliate Kris Saha, PhD, have published a proof-of-concept method to correct Best disease – an inherited form of macular degeneration that causes blindness, and that is …
Waisman Biomanufacturing partners with Heat Biologics to manufacture COVID-19 vaccine
Waisman Biomanufacturing at the University of Wisconsin–Madison is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials. Phase 1 trials could begin in early 2021 and UW–Madison may be a trial site.
The ECHO Effect
Project ECHO (the mantra for which is “All teach, all learn”) uses video-conferencing technology to provide education and case consultation on best practice clinical services, training, and resources for individuals with specific healthcare needs that are difficult to meet locally. The Waisman Center ECHO platform will serve as a diagnostic and treatment training hub to share the center’s expertise on intellectual and developmental disabilities, such as autism, Down syndrome, and cerebral palsy, throughout the state and beyond.
Research Core Revitalization Program funds upgrades to shared resources on campus
Projects from three research cores at the Waisman Center are among 17 UW core projects to receive grants from the Research Core Revitalization Program—an initiative with support from the Office of the Vice Chancellor for …
Balancing act: what motor function can tell us about autism
Can the way a person moves be a key identifier of autism? It’s a question that Waisman Center investigator Brittany Travers, PhD, is trying to answer. A new paper from Travers’ lab suggests that movement patterns of individuals with autism spectrum disorder (ASD) may differ from those with typical development.
Serving During COVID-19: AAC Outreach Services
The Communication Development Program (CDP) is an outreach program of the Waisman Center UCEDD at University of Wisconsin, Madison. This program was developed over 30 years ago in partnership with the Dane County Department of …